Rapp-Hodgkin and AEC syndromes due to a new frameshift mutation in the TP63 gene

I Dianzani, E Garelli, P Gustavsson, A Carando, B Gustafsson, N Dahl, G Annerén

KEY POINTS

- TP63 gene mutations have been identified in several malformation syndromes. An apparently conclusive genotype-phenotype correlation has been deduced from the fact that they are caused by mutations in specific protein domains.
- Our investigation of three multiplex families revealed causal mutations. The family exhibiting Rapp–Hodgkin syndrome (RHS) carried a new mutation, a deletion of an A located in exon 14 (1859delA).
- This is the first demonstration that RHS is due to a p63 defect. RHS is differentiated from ankyloblepharon-ectodermal dysplasia-cleft (AEC) syndrome by the absence of ankyloblepharon philiforme adnatum. The finding of this anomaly in one patient from the RHS family suggests that AEC and RHS are the same clinical entity.

An apparently conclusive genotype-phenotype correlation has been deduced to explain the development of different syndromes (with some exceptions). All but one of the EEC mutations affect the TP63 DNA binding domain, whereas all but one of the AEC mutations are caused by missense mutations affecting the SAM domain. SHFM patients have either missense mutations in the DNA binding domain or nonsense mutations within the C terminus. Three mutations have been found in LMS patients: two frameshift mutations in exon 13 or 14, and a missense mutation in exon 4. ADULT syndrome mutants include one missense mutation in the TA2 domain located at the N terminal region of the ΔN isoform, and a specific missense mutation in the DNA binding domain.

EEC and SHFM missense mutations are expected to lose TA functions; AEC and LMS mutants maintain TA functions, but lose the regulatory functions ascribed to the SAM domain and the TID, respectively. ADULT mutations are mutations that gain function, because they both activate the TA2 domain. These hypotheses have been supported by expression of mutant proteins and analysis of their function in the laboratory or by analogy with p73 and p53 mutants. SHFM is genetically heterogeneous: only 10% of SHFM are due to TP63.

Rapp–Hodgkin syndrome (RHS: MIM 129400) is autosomal dominant and shares two cardinal symptoms with

Encreases in the number of allelic malformation syndromes (due to mutations in a single gene) have led to their classification according to their pathogenesis rather than their clinical specific phenotype. TP63 mutations have been identified in several such syndromes characterised by autosomal dominant transmission and various combinations of ectodermal dysplasia, limb malformations, and orofacial clefting.

The TP63 gene is a TP53 homologue, part of a family composed of only three members. The third member (TP73) is more similar to TP63 than to TP53 in both structure and function. Like p53, p63 has a transactivating (TA), a DNA binding (DB), and a polymerisation domain; it exerts p53-like activities in various contexts, such as binding canonical p53 sites, transactivating p53 target genes, and inducing apoptosis. Unlike TP53, which expresses one major transcript, TP63 contains four separate transcription initiation sites that direct expression of two fundamentally different isotypes that retain (TA products) or lack (ΔN products) the TA domain. Alternative splicing generates additional complexity at the C terminus.

ΔN isoforms lack TA activity and may also suppress the TA isoforms, either by simple competition for the DNA target sites or by acting as dominant negatives through oligomerisation. By contrast to p53, the C terminus in p63 is longer and contains a SAM domain and a TID (transactivation inhibitory domain). SAM domains are involved in protein-protein interactions and probably have regulatory functions in p63. Since its TA-ΔN isoform shows a lower TA activity than the γ form, which lacks the SAM but retains the TA domain. The TID has been mapped within the α tail downstream of the SAM domain. The differences at the C terminus identify three transcripts which have different properties and functions: α, β, and γ isoforms. The α isoforms have the SAM and the TID, and lack the region corresponding to exon 15, which is shown by the γ isoforms. The latter are formed by splicing out the regions encoded by exons 11–14. The β isoforms lack the region corresponding to exon 13 and use a different frame that finds a stop codon at the beginning of exon 14; they lack both the SAM and the TID. Lastly, p53 is conditionally expressed, whereas p63 is constitutively present. It is expressed mainly in the stem cell compartment of epithelial tissues. ΔN products are the most abundant isoforms, and highlight a role for repressive versions in epithelial stem cell identity.

TP63 is rarely mutated in cancer, and its main role is in embryo development. In fact, TP63 mutations have been identified in the following malformation syndromes: ectodermal dysplasia, ectrodactyly, cleft lip / palate (EEC: MIM 604292); split-hand / foot malformation (SHFM: MIM 183600); ankyloblepharon-ectodermal dysplasia-cleft (AEC: MIM 106260); limb-mammary syndrome (LM: MIM 603543); and acro-dermato-ungual-lacrimal-tooth syndrome (ADULT: MIM 103285). Patients do not show an increased susceptibility to cancer.
EEC: cleft lip / palate and ectodermal dysplasia. Its other features are hypohidrosis, a peculiar face with a narrow nose and a small mouth, short stature, hypoplasias, pili torti or pili canaliculi (uncombable hair), and normal intelligence.\textsuperscript{20–34} The association of hypohidrosis, sparse hair, nail dysplasia, and cleft palate was first described by Rapp and Hodgkin in a mother and her two siblings.\textsuperscript{35} RHS is treated as a syndrome to be ruled out in the diagnosis of EEC.\textsuperscript{29–34} EEC is sometimes observed unaccompanied by ectrodactyly.\textsuperscript{36–39} However, the birth of a son with EEC to a woman with RHS has suggested that the two phenotypes could be allelic.\textsuperscript{40} Molecular analysis of TP63 has not been extensively performed to confirm or disprove this hypothesis. Finally, R Gorlin lists RHS and AEC as a single clinical entity, since only the occurrence of ankyloblepharon filiforme adnatum in the latter distinguishes them.\textsuperscript{41} He clearly states that molecular evidence is awaited to confirm this hypothesis.

This paper describes the mutations found in three Swedish multiplex families: two had EEC, one had RHS. One patient from the RHS family had a slight ankyloblepharon on one eye at birth, and, according to Gorlin’s criteria, should be considered affected by AEC. Our work is the first to demonstrate that RHS is due to a TP63 defect and that AEC and RHS are the same clinical entity.

**MATERIALS AND METHODS**

**Subjects**

Families A and C were diagnosed and reported on by GA \textit{et al.} at the Department of Genetics and Pathology, Uppsala University, Sweden,\textsuperscript{42} and family B was diagnosed by BG at the Karolinska Institute, Stockholm, Sweden. Pedigrees are shown in fig 1 and clinical data in table 1. Informed consent was obtained from all family members before their participation.

Diagnosis of EEC syndrome was obtained following previously described diagnostic criteria.\textsuperscript{36} Both family B and family C included patients with the classic triad. A typical RHS was diagnosed in family A (fig 2) from the combination of ectodermal dysplasia and cleft, absence of ankyloblepharon filiforme adnatum, and hand and nipple anomalies. All three subjects displayed typical facial features, such as narrow or hypoplastic nostrils, maxillary hypoplasia, small mouth, thin lips, small teeth with enamel defects and missing teeth, uncombable dry hair with pili torti, and reduced production of tears and saliva. The mother had a

![Figure 1 Pedigrees of the three families.](image-url)
cleft palate and the younger daughter had a cleft lip and palate. The mother lost her hair after recurrent scalp infections. Both she and her elder daughter had many pigmented naevi. The patients had normal nipples and the mother breastfed her children. The cleft and absence of hand and nipple anomalies excluded LMS in all patients. The absence of ankyloblepharon filiforme excluded AEC, and the patients were diagnosed as affected by RHS. However, a thorough study of the patients’ clinical histories ascertained that the mother had a slight ankyloblepharon on the right eye at birth, which was surgically treated. According to Gorlin’s criteria, she was affected by AEC.

Segregation and mutational analysis
Blood samples were drawn from all participants and genomic DNA extracted by standard methods. Segregation of 3q highly polymorphic markers (D3S3530 and D3S1294) were analysed by PCR amplification followed by acrylamide electrophoresis and silver staining. TP63 genomic screening was performed by PCR amplification of single exons and intron-exon boundaries, followed by sequencing using an ABI PRISM-BigDye Terminator Cycle Sequencing Ready Reaction kit and an ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Warrington, UK). Each exon was sequenced twice using 5' and 3' -primers (the primer sequence has been reported) and amino acid position was numbered according to recent literature. Mutation segregation was ascertained by digestion with restriction enzymes. R279C (CGC -> TGC) was identified by PstI, which recognises and cuts the mutant sequence when a mutagenesis primer is used for PCR; R304Q (CGG -> CAG) was recognised by HpaII, which cuts the normal sequence.

RESULTS
Segregation of 3q highly polymorphic markers (D3S3530 and D3S1294) was concordant with the disease in all three families (data not shown). This suggested that RHS was allelic with EEC. Causal mutations were found: the EEC families carried mutations in the DNA binding domain of p63, namely R279C in exon 7 and R304Q in exon 8, respectively. These mutations are recurrent, since they have been found in several unrelated families. Full penetrance was always observed, although expression was variable even in the monozygotic twins of family C. This points to a stochastic event in embryo development, since the twins shared the same genetic background. Microsatellite segregation and mutation analysis showed that the mutation was a new event in the paternal meiosis of patient II-5 in family B. Grandparents were not available for the other families.
Complete sequencing of DNA from RHS patient II-1 (family A) revealed deletion of an A at position 1859 in exon 14, within codon 620, as illustrated in fig 3(A). Deletion causes a frameshift and affects the α tail.

Exon 14 was subsequently sequenced in all the members of the family. The deletion was found in all three affected members and not in the normal sibling. This new mutation is the most 3′ frameshift mutation found so far in TP63.

**DISCUSSION**

This paper records the identification of a mutation in TP63 in an RHS family with three affected members; the molecular basis of RHS is thus defined. There has been no previous published demonstration of the molecular basis of RHS, although a recent paper reported analysis of the TP63 gene in a sporadic patient without any mutation being disclosed.**10** It is possible that there was a causal mutation in the introns and regulatory sequences, which were not screened in that paper.

The mother in family A had a slight ankyloblepharon of one eye at birth. According to Gorlin's criteria, she was affected by AEC rather than RHS.**4** Thus, our data not only allow classification of RHS among allelic syndromes due to TP63 mutations, but also confirm the hypothesis that AEC and RHS are the same clinical entity.

The 1859delA mutation found in the RHS patients predicts an abnormal α tail. Other α tail mutations have been found in patients with LMS, EEC, AEC, and SHFM, namely: a TT deletion at bases 1576–1577 in exon 13 and a deletion of two As at 1743–1744 in exon 14 in LMS patients; an insertion of an A at base 1572 of exon 13 in an EEC patient; a 1742delC in an AEC patient; and two nonsense mutations (Q634X and E639X) in SHFM patients.**11** All these mutations affect only the α isoforms of p63, but with different molecular consequences.

The TT deletion in LMS and the A insertion in EEC are both in exon 13. They predict the use of the same frame which reveals a stop codon at base 1611 within exon 13, and an effect on the SAM domain, if expressed. The insA mutant has been expressed in the laboratory and conferred a gain of function on the SAM domain, if expressed. The insA mutant has been expressed in the laboratory and conferred a gain of function on the SAM domain, if expressed. The insA mutant has been expressed in the laboratory and conferred a gain of function on the SAM domain, if expressed. The insA mutant has been expressed in the laboratory and conferred a gain of function on the SAM domain, if expressed.

The delC mutant in exon 14 found in an AEC patient predicts the use of the same frame as that used by the delC mutant in RHS patients; this predicts a stop codon at base 1991 (TTA), 65 bp downstream to the canonical TGA stop. The two mutant transcripts, however, encode different proteins: delC predicts the addition of 83 amino acids after codon 580, whereas delA predicts the addition of 44 amino acids after codon 619, as shown in fig 3(B).

The TID repressive activity mapped to the α tail downstream to the SAM domain**12** is lost in all the frameshift mutations, including this new mutation. Thus a gain of function is also expected for these mutants, if they are indeed expressed. It is intriguing that the use of the same frame by different mutations is responsible for similar phenotypes: insA and delTT for EEC and LMS, and delC and delA for AEC and RHS, respectively.

Recently, an unusual mutation affecting ex 11 splicing was found in an AEC patient, IVS10-2**:13**; the skipping of exon 11 results in a frameshift. The molecular consequences are different from those expected from the α tail frameshifts, because not only the α but also the β isoforms are affected by IVS10-2.

Our data show that RHS is due to a defect in TP63. Thus, the spectrum of malformative diseases due to TP63 abnormalities is further extended.**14, 15** We also show that RHS and AEC are probably the same clinical entity. Further studies are needed to elucidate the developmental pathways that involve the different functions of p63 isoforms. These may clarify the pathogenesis of diseases due to TP63 mutations and their apparent genotype-phenotype correlation.

**ACKNOWLEDGEMENTS**

We wish to thank Dr M Silengo for helpful discussion.

**REFERENCES**


www.jmedgenet.com
RHS is due to mutations in TP63

30 Salinas CF, Montes GM. Rapp-Hodgkin syndrome: observations on ten cases and characteristic hair changes (pili canaliculi). *Birth Defects Orig Art Ser* 1988;24:149–68.